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Insua J.
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Objectives: Standardized outcomes of global vascular disease (GVD) are dif-
ficult to obtain in middle income countries. Mortality and readmissions are 
regarded as important quality outcomes. We used the standardized results of 
a hospitalization study to obtain in-hospital mortality and readmissions at 365 
and 30 days. MethOds: We developed a standardized registry from a cross-sec-
tional study (Value in Health 2011;14:A18). The universe of patients is all Clinical 
Classification Software Grouper, CCS #100-116 of hospital discharge minimum 
data set (MDS), 19 yrs old (GVD). The 30 day readmission (< 30 d ReH), defined as: 
the number of stays with at least one subsequent hospital stay within 30 days (n)/ 
the total number of hospital stays in the one year period observed (N), 365 day 
readmissions (365 ReH) follow the same definition with corresponding change in 
n. Denominator excluded < 19 years old and dead patients in index admission. 
Overall mortality (denominator all discharges) and case fatality rations (deaths /
each CCS or CCS group), rates and corresponding 95%CI are analyzed. Results: 
Among 45466 discharges, those with CCS #100-116 (11,02%) had 440 deaths ( mor-
tality 0,97% (95%CI 0,88-1,06%) , of this 5009 discharges the case fatality ratio was 
8,78% (95%CI 8,00-9,57%). A-VD events led to a < 30 ReH rate of 11,34% ( 95%CI 
10,46-12,21%) and a 365 days ReH rate of 40,75% (95%CI 39,49-42,11%). Among 
groups the highest case fatality ratio was that of cerebrovascular disorders: 16,79% 
(95%CI 14,22-19,35%); congestive heart failure showed the highest < 30 ReH rate: 
18,08% (95%CI 15,88-20,88%); and the highest 365 ReH rate 60,87% (95%CI 58,08-
63,65%). The most lethal CCS was #107: 91,04% (95%CI 84,21-97,88%), (all individual/ 
group results not provided here). cOnclusiOns: After obtaining prevalence esti-
mates of major GVD using CCS groupers, a standardized methodology, we where 
able to obtain mortality, case fatality and and first readmission estimates for major 
cardiovascular discharges of the country.
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dePressiOn treatment amOnG WOmen WitH CardiO-metabOliC 
COnditiOns: findinGs frOm mediCal exPenditure Panel surVey 2012
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Objectives: Little is known about the current practices of managing depres-
sion among the women with cardio-vascular conditions. Therefore, the cur-
rent study was conducted to identity types of depression treatment among the 
women with cardio-metabolic conditions using a nationally representative survey 
data. MethOds: Using data of 2012 Medical Expenditure survey a retrospective 
cross sectional study was performed. The study sample consisted of 944 women 
aged 21 or older with depression and presence of any of the following cardio-met-
abolic conditions: hypertension, heart disease, and diabetes. Depression treatment 
was classified into three categories: 1) No treatment, 2) Antidepressant use only 
and 3) Psychotherapy with or without antidepressant. The differences in the rates 
of depression treatment by demographic, socio-economic, and health-status were 
analyzed using chi-square tests. Factors associated with depression treatment 
were identified using multinomial logistic regression. Results: A greater propor-
tion of women with cardio-metabolic conditions received only antidepressant as 
a primary depression treatment (55%), and combination therapy (24%), whereas, 
21% women did not receive any depression treatment. Women with co-existing 
anxiety (Adjusted odds ratio: AOR: 5.23, 95% CI: 2.37, 11.52), women with poor or 
fair mental health status (AOR: 4.43, 95% CI: 1.45, 13.47), and women with living in 
rural areas (AOR: 2.92, 95% CI: 1.21,7.05) were significantly more likely to receive 
psychotherapy with or without antidepressant. Whereas, women with lower than 
high school education and fair or poor physical health status were less likely to 
receive psychotherapy with or without antidepressant. Women with no usual 
source of care were significantly less likely to receive only antidepressant treat-
ment. cOnclusiOns: Nearly one forth of women diagnosed with depression and 
cardio-metabolic condition(s) did not receive any treatment of depression. Given 
the adverse prognostic outcomes of depression in women with chronic conditions, 
healthcare policy should be designed to improve use of active treatment in women 
with cardio-metabolic conditions.
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Objectives: Recent studies have reported that a very high number of hyperten-
sive patients’ discontinue their treatment which may be attributed to issues such 
as unattained blood pressure goals, adverse drug events, drug cost, or personal 
factors. Treatment modifications (TMs) – addition, uptitration, switching, and 
downtitration – are necessary to address these issues. This study assessed patterns 
of TMs across the antihypertensive drug classes (ADCs) used as first-line treat-
ment. We compared the rates of TM and time-to-TM across ADCs. Additionally, 
we determined the association between TM strategies and the likelihood of 
treatment discontinuation. MethOds: This is a retrospective cohort study using 
the BlueCross-BlueShield of Texas commercial claims database (2008-2012). We 
identified TMs that occurred within one year of starting hypertension treatment. 
Patients who received a TM were followed for 12 months to determine if and 
when they discontinued treatment. Cox regression models were used to identify 
the likelihood of TM, time-to-TM, and the likelihood of treatment discontinua-
tion. Results: About 48.5% patients received at least one TM within one year of 
Objectives: To summarize the pharmacoeconomics research articles published on 
diabetes and hypertension in India. MethOds: A PubMed database was searched 
for pharmacoeconomics research on diabetes and hypertension in India. The articles 
that were published and were available on Pubmed database from the year 1990 to 
2014 were searched by using MeSH (Medical Subject Headings) terms viz., pharmaco-
economics, cost effective analysis, cost analysis, health care cost, economic analysis 
and cost of illness. All the studies shown in the search results were considered for 
the study irrespective of the type of pharmacoeconomic evaluation. Results: A 
total of 446 pharmacoeconomics research articles were found based on the MeSH 
terms. Out of 446, 15 (68.18%) studies were related to diabetes and 7 (31.82%) stud-
ies were related to hypertension. In India, most of the studies were conducted in 
Tamil Nadu state (n= 12, 54.54%) followed by Karnataka (n= 2, 9.09%), Chandigarh 
(n= 2, 9.09%), Kerala (n= 2; 9.09%), New Delhi (n= 1, 4.54%), Maharashtra (n= 1, 4.54%), 
Gujarat (n= 1, 4.54%) and Telangana state (n= 1, 4.54%). Most of the articles were 
published in between the year 2011-2014 (n= 10, 45.45%) followed by 2007-2010 (n= 6, 
27.27%) and 2000-2002 (n= 6, 27.27%). There were no published articles on pharma-
coeconomic studies from the year 2003 to 2006. cOnclusiOns: The pharmacoeco-
nomic studies published in India are relatively less compared to that of developed 
countries. There is a need for furthering pharmacoeconomic research on the most 
prevalent chronic diseases such as diabetes and hypertension in India. Researchers 
should also gear-up to publish pharmacoeconomics related research in reputed 
journals with high impact factor.
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Objectives: Diabetes is one of the most prevalent chronic diseases in the United 
States. The probability of developing diabetes is closely related to body mass index 
(BMI). This study investigated the population-specific likelihood of developing dia-
betes in relation to other obesity-related comorbidities (hypertension, stroke, and 
coronary heart disease (CHD)) in the United States from 2007 to 2010. MethOds: Data 
from the National Health and Nutrition Examination Survey (NHANES), 2007-2010, 
were used to analyze the risks of diabetes. The probability of developing diabetes 
was estimated by fitting an exponential survival function to the age first diagnosed 
with diabetes and controlling for race (white, black, and other), BMI category (normal 
weight: 18.5-24.9 kg/m2, overweight: 25-29.9 kg/m2, and obese: ≥ 30 kg/m2), and prior 
diagnosis of stroke, CHD, and hypertension. Complex sampling design in the NHANES 
data was adjusted for in all analyses. Results: We found that males were more likely 
to develop diabetes compared with females. Races other than blacks and whites had 
the highest risk of diabetes. The likelihood of developing diabetes increased with 
BMI. Obese individuals had a two times higher risk than normal weight individu-
als for most gender and race groups. Among hypertension, stroke, and CHD, hyper-
tension was found to be the most highly correlated with diabetes risk. Individuals 
with hypertension were three times more likely to develop diabetes compared with 
individuals without any comorbid conditions. Using normal weight white females 
as an example, the probability of developing diabetes without any obesity-related 
comorbidity was 0.04% compared with 0.13% for individuals with hypertension. A 
similar pattern of diabetes risks was found in patients with both hypertension and 
stroke. cOnclusiOns: Our results showed that the risk of diabetes increased with 
BMI category, and that individuals with hypertension were three times more likely to 
develop diabetes compared with individuals without any preexisting comorbidities.
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Objectives: Aging population in India is growing faster than other countries in 
the world. Aging impairs functional independence, impact activities of daily living 
(ADLs) and reduces quality of life. The goal of this study was to assess functional 
status and ADLs among aging population of India. MethOds: The Longitudinal 
Aging Study in India (LASI) data was used to assess functional status and ADLs in 
elderly population. Data collected as part of LASI questionnaire on self-reported 
and European health scale, and Wallace and Herzog ADL scale was analyzed for 
descriptive statistics and for differences using the Chi square test and ANOVA. A 
regression analysis was performed to identify relationships between demographic 
characteristics, functional status and ADLs. A p value of < 0.05 was considered 
statistically significant. Results: A total of 1,683 older adults of 950 randomly sam-
pled households were included in this study. Hypertension, heart disease, stroke, 
lung disease, arthritis and psychiatric conditions were more prevalent with signifi-
cant regional differences (p< 0.05). Forty percent of respondents had work limiting 
health conditions. Respondents reporting poor health ranged between 18%-26% 
on two different health scales. Majority of the respondents reported difficulty with 
one or more of the five activities such as difficulty in bathing and getting in and 
out of the bed. Differences in functional status and ADLs were significant among 
respondents from four different states. Thirty six percent respondents from Kerala 
had work limiting health conditions and 40% from Karnataka had difficulty with 
ADLs (p< 0.05). Regression analysis showed significant relationship between arthri-
tis, lung disease, health condition limiting work, region of residence and difficulty 
with ADLs (p< 0.05). cOnclusiOns: There are significant differences in functional 
status and ADLs among aging population of India. The findings of this study can 
help policy makers to design and implement interventions and policies that help 
elderly to improve ADLs.
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Objectives: This study aims to understand unmet medical needs despite 
available treatment options of venous thromboembolism (VTE) treatment in 
Europe. MethOds: This retrospective cohort study included data from physi-
cians (376 general practitioners and 307 specialists) in France, Germany, Italy, 
and Spain, who completed case report forms for the next 3-4 patients seen in 
consultation meeting inclusion criteria. Patients were assigned to mutually 
exclusive groups based on a hierarchy (vitamin K antagonist (VKA), rivaroxa-
ban, low-molecular-weight-heparin (LMWH), aspirin, other anti-coagulants, no 
known treatment, respectively) determined by treatment data (dosing, start/end 
dates, and prescription duration and prescriber information, either in hospital 
or at discharge, following VTE, or as new treatment for first-time VTE event). 
Logistic regression with backward elimination identified significant predictors 
of treatment allocation. Results: Patients’ mean age (total n= 2184) was 61.3 
years (SD= 14.3) and 47.4% were females. The hierarchy of treatments revealed 
that 63.1% of patients were using VKA, 30.6% using rivaroxaban or LMWH but no 
VKA, and 6.2% using other combinations. Mean treatment period was higher for 
VKA (168 days) than for rivaroxaban (139 days) or LMWH (46 days) patients. LMWH 
treatment was significantly more common than VKA among cancer patients (odds 
ratio (OR):2.35, P< .001), but less likely among pulmonary embolism or deep vein 
thrombosis patients with (OR:0.35, P= .001) or without complications (OR:0.33, 
P= .001), hospitalization for first VTE (OR:0.32, P< .001), and hip/knee replacement 
(OR:0.39, P= .028). Predictors of VKA vs. rivaroxaban included: more months since 
initial VTE event (OR:1.06, P< .001), no hormone replacement therapy (OR:5.83, 
P< .001), no chronic heart failure (OR:2.09, P= .001), and age of 40+ (OR:1.61, 
P= .03). cOnclusiOns: Treatment patterns in the European Union show that VKA 
is a common treatment for VTE in addition to other anticoagulants. Attention to 
risk factors can play a major role in determining continuation of therapy which 
is likely to reduce VTE recurrence.
musCular-skeletal disOrders – Clinical Outcomes studies
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treatment WitH sOme bisPHOsPHOnates is assOCiated WitH aOrtiC 
and mitral ValVe CalCifiCatiOn
Ali A.K.
Eli Lilly and Company, Indianapolis, IN, USA
Objectives: A signal of bisphosphonate-related cardiac valve calcification lead-
ing to cardiac valve insufficiency was detected in the European adverse event 
monitoring system (EudraVigilance); however no signal detection activity was 
conducted in the US. This pharmacovigilance analysis investigates and relation-
ship between bisphosphonates and aortic and mitral valve calcification in the FDA 
Adverse Event Reporting System (FAERS). MethOds: Bisphosphonate-related 
adverse event reports submitted to FAERS between 1997 and 2013 were used to 
investigate the disproportional reporting of cardiac valve disorders (CVD) in rela-
tion to bisphosphonates therapy, including aortic and mitral valve calcification. 
Multi-item Gamma Poisson Shrinker data mining algorithm was used to calculate 
Empirical Bayes Geometric Mean (EBGM) and corresponding 95% confidence interval 
as disproportionality measures. Signals that warrant further review are defined 
as measures with confidence interval lower limit≥ 2.0. The Anatomical Chemical 
and Therapeutic classification was used to define bisphosphonate exposure, and 
the Medical Dictionary for Regulatory Activities, Preferred Term coding hierar-
chy was used to define cardiac valve calcification. Results: A total of 2,010 CVD 
events were submitted for bisphosphonates. Of those, 116 events were for cardiac 
valve calcification, affecting aortic valve (n= 32); mitral valve (n= 83); and pulmo-
nary valve (n= 1). Signals were detected for alendronate (aortic: n= 8, EBGM= 3.7, 
95%CI= 2.03-6.34; mitral: n= 15, EBGM= 3.99, 95%CI= 2.58-5.96); pamidronate (aortic: 
n= 7, EBGM= 9.94, 95%CI= 3.27-30.3; mitral: n= 25, EBGM= 36.8, 95%CI= 26.1-50.6); and 
Zoledronate (aortic: n= 13, EBGM= 4.44, 95%CI= 2.77-6.86; mitral: n= 39, EBGM= 7.23, 
95%CI= 5.45-9.58). No signal was detected for ibadronate (aortic: n= 1, EBGM= 0.92, 
95%CI= 0.21-2.92; mitral: n= 2, EBGM= 1.02, 95%CI= 0.32-2.58) and risedronate (aor-
tic: n= 3, EBGM= 2.6, 95%CI= 0.99-5.9; mitral: n= 2, EBGM= 1.43, 95%CI= 0.45-3.61; pul-
monary: n= 1, EBGM= 1.36, 95%CI= 0.3-4.38). cOnclusiOns: Treatment with some 
bisphosphonates might be associated with aortic and mitral valve calcification. It 
might be necessary for prescribers to monitor patients for CVD before and periodi-
cally during bisphosphonates therapy. Signal clarification and evaluation activities 
by pharmacoepidemiologic studies are recommended.
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safety Of tOfaCitinib COmPared tO biOlOGiCal dmards in rHeumatOid 
artHritis Patients WitH an inadequate resPOnse tO metHOtrexate: 
OVerVieW Of systematiC reVieWs
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1Pfizer SAS, Bogota, Colombia, 2Universidad Nacional de Colombia, Bogota, Colombia
Objectives: The aim of this network meta-analysis was to compare the safety of 
tofacitinib to biological DMARDs for treatment of rheumatoid arthritis in patient 
with inadequate response to methotrexate. MethOds: We performed an overview 
of systematic reviews that evaluated biological DMARDs or tofacitinib for treat-
ment of rheumatoid arthritis patients with inadequate response to methotrexate. 
The searching was carried out using the database of MEDLINE, EMBASE, Lilacs, 
COCHRANE, DARE and HTA restrictive to systematic review published in the last 
five years. The strategy of search was the similar to guideline of rheumatoid arthritis 
of the Ministry of Health of Colombia. Two researchers selected independently the 
studies and extracted the data. La risk of bias of systematic review was assessed 
with AMSTAR and ISPOR tools. The clinical trials were evaluated with The Cochrane 
Collaboration’s tool for assessing risk of bias . Bayesian mixed treatment compari-
son method was applied for the pairwise comparison of treatments, where the 
common comparator was methotrexate. The outcomes were occurrence of serious 
adverse events, serious infections and withdrawal due to adverse event. Results: 
treatment initiation. The rates of TM were significantly different across ADCs; 
angiotensin converting enzyme inhibitor and angiotensin receptor blocker users 
were less likely to receive TMs compared to other drug classes. The mean time-
to-TM was > 100 days for patients adding or uptitrating medications, and > 150 
days for those switching or downtitrating medications. The likelihood of discon-
tinuation was significantly lower for patients intensifying treatment by adding 
medications vs. those uptitrating dose (HR= 0.765; CI: 0.701-0.834). cOnclusiOns: 
TMs are common among newly treated hypertensive patients. The rates of TM 
vary significantly across ADCs. In the real-world, TMs occur much later than the 
30-day time-line recommended by clinical guidelines. Addition of drugs may be a 
preferred approach vs. uptitrating drug dose for intensifying treatment of patients 
who are at a high risk of treatment discontinuation.
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Objectives: Objective: Despite the efficacy and safety of statins, real-world data 
suggest they are suboptimally used among dyslipidemic patients. The current 
study sought to describe patterns of statin utilization among high cardiovascular 
(CV)-risk patients initiating statin therapy. MethOd: methods: Adult patients (≥ 18 
years) with continuous enrollment who were newly initiating statins were identi-
fied from the Truven MarketScan Research databases (01/2007-06/2013). Patients 
were selected for and stratified into 1 of 5 mutually exclusive, high CV-risk–based 
hierarchical categories: recent acute CV event ( hospitalization for acute coronary 
syndrome [ACS] or other CV event within 90 days of index), coronary heart disease 
(CHD), ischemic stroke, peripheral vascular disease/peripheral artery disease (PVD/
PAD), and diabetes. Descriptive statistics and time-to-event analyses were used to 
measure proportion of days covered (PDC), time to discontinuation, and hospitaliza-
tion rates. Results: results: Among 541,221 high CV-risk patients, 61% were in the 
diabetes cohort, followed by recent acute CV event (26%), PVD/PAD (5%), CHD (4%), 
and ischemic stroke (4%). High-intensity statins (atorvastatin 40/80 mg, rosuvastatin 
20/40 mg, simvastatin 80 mg) were initiated in 15% of patients, with the percentages 
varying among subgroups (10% [diabetes] to 31% [ACS]). More than 20% of high-
intensity statin initiators switched to a moderate- to low-intensity statin (range, 
19% [PVD/PAD] to 28% [other CV event]). The PDC ranged from 56% (diabetes) to 
66% (ACS). Median time to statin discontinuation among high CV-risk patients was 
approximately 15 months. Median time to discontinuation among patients receiv-
ing high-intensity versus moderate- to low-intensity statin was 21 months and 15 
months, respectively. At 1 year, Kaplan-Meier estimates of cumulative event rates 
for CV-related hospitalizations were lowest in the diabetes cohort and highest for 
patients with recent ACS hospitalization (4% and 22%, respectively). cOnclusiOns: 
Conclusion: Low PDC and discontinuation of statin therapy were observed among 
high CV-risk patients. Interventional opportunities to ensure better therapy man-
agement are warranted.
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Objectives: In patients with spontaneous intracerebral hemorrhage (ICH), cur-
rent guidelines recommend managing elevated blood pressure (BP) with inter-
mittent or continuous infusion of intravenous medications. The purpose of this 
retrospective observational study is to evaluate the clevidipine (CLV) usage pat-
terns and patient outcomes of continuous infusion intravenous antihyperten-
sive agents (IVAH) compared to other agents available. MethOds: Study data 
were extracted from the Premier hospital database. ICH patients were identified 
by primary diagnosis ICD-9 CM codes of 431 (ICH) or 432 (other or unspecified 
ICH) and a final MS-DRG of 64, 65, 66 (Intracranial hemorrhage or cerebral infarc-
tion). Patients who received clevidipine, nicardipine, or nitroprusside during the 
first two days of admission between January 2009 and June 2014 were included. 
Baseline demographics, outcomes, and costs were evaluated and propensity score 
matching comparing CLV to nicardipine (NIC) and CLV to nitroprusside (SNP) was 
performed to control for confounders. Results: 165 clevidipine, 15910 nicardi-
pine, and 1091 nitroprusside inpatients from 520 US hospitals met the inclusion 
criteria. Treatment pattern analysis showed nitroprusside usage decreased from 
15.8% in 2009 to 1.3% in 2014, while NIC and CLV usage increased over the same 
time; CLV from 0.8% to 2.7% . After propensity matching, 126 patients remained 
in each group for the CLV-NIC pair and 90 patients in the CLV-SNP pair. Mortality 
rates were similar in both comparisons at 27.8% (CLV) vs 28.6% (NIC) and 31.1% 
(CLV) vs. 37.8% (SNP). After excluding in-hospital deaths, mean length of stay 
was 7.8 days (CLV) vs 8.8 days (NIC) and 8.0 days (CLV) vs 8.2 days (SNP). Inflation 
adjusted mean total costs were $16903 (CLV) vs $18634 (NIC) and $15972 (CLV) vs 
$15965 (SNP). cOnclusiOns: Although CLV is < 3% of use in this sample, PSM 
demonstrates similar outcomes in comparison with NIC and SNP.
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